News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Immunic announces positive results from Phase 2 CALLIPER trial showing 30% reduced risk of disability worsening in Primary Progressive Multiple Sclerosis patients with vidofludimus calcium. Webcast scheduled for April 30 -